© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#ASH 2017
Click Here for More Conferences
Click Here for ASH Online
Blood Cancers 101
Red blood cells

Bluebird CAR-T Therapy Has High Multiple Myeloma Remission Rate

Most Phase I study participants responded to the experimental immunotherapy.
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Yescarta manufacturing

Yescarta CAR-T Therapy Leads to Durable Remission of Advanced Lymphoma

Long-term follow-up from ZUMA-1 trial shows patients remain cancer-free for up to two years.
A patient’s T cells arrive at the Novartis manufacturing facility in Morris Plains, where they will be re-engineered to recognize and fight cancer and healthy cells expressing a specific antigen in the patient’s body.

Kymriah CAR-T Therapy Leads to Long-Term Remission in Adults With Lymphoma

Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.

Hot topics

#Immunotherapy
#Chemotherapy
Red and white blood cells

Targeted Therapies Improve Outcomes for People With Chronic Lymphocytic Leukemia

Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.
Advertisement
Science News
Newsfeed